Thomas Christian, Soschinski Patrick, Zwaig Melissa, Oikonomopoulos Spyridon, Okonechnikov Konstantin, Pajtler Kristian W, Sill Martin, Schweizer Leonille, Koch Arend, Neumann Julia, Schüller Ulrich, Sahm Felix, Rauschenbach Laurèl, Keyvani Kathy, Proescholdt Martin, Riemenschneider Markus J, Segewiß Jochen, Ruckert Christian, Grauer Oliver, Monoranu Camelia-Maria, Lamszus Katrin, Patrizi Annarita, Kordes Uwe, Siebert Reiner, Kool Marcel, Ragoussis Jiannis, Foulkes William D, Paulus Werner, Rivera Barbara, Hasselblatt Martin
Institute of Neuropathology, University Hospital Münster, Münster, Germany.
McGill University Genome Centre, Department of Human Genetics, McGill University, Montreal, Canada.
Neuro Oncol. 2021 Apr 12;23(4):650-660. doi: 10.1093/neuonc/noaa267.
Choroid plexus tumors (CPTs) are intraventricular brain tumors predominantly arising in children but also affecting adults. In most cases, driver mutations have not been identified, although there are reports of frequent chromosome-wide copy-number alterations and TP53 mutations, especially in choroid plexus carcinomas (CPCs).
DNA methylation profiling and RNA-sequencing was performed in a series of 47 CPTs. Samples comprised 35 choroid plexus papillomas (CPPs), 6 atypical choroid plexus papillomas (aCPPs) and 6 CPCs plus three recurrences thereof. Targeted TP53 and TERT promotor sequencing was performed in all samples. Whole exome sequencing (WES) and linked-read whole genome sequencing (WGS) was performed in 25 and 4 samples, respectively.
Tumors comprised the molecular subgroups "pediatric A" (N=11), "pediatric B" (N=12) and "adult" (N=27). Copy-number alterations mainly represented whole-chromosomal alterations with subgroup-specific enrichments (gains of Chr1, 2 and 21q in "pediatric B" and gains of Chr5 and 9 and loss of Chr21q in "adult"). RNA sequencing yielded a novel CCDC47-PRKCA fusion transcript in one adult choroid plexus papilloma patient with aggressive clinical course; an underlying Chr17 inversion was demonstrated by linked-read WGS. WES and targeted sequencing showed TP53 mutations in 7/47 CPTs (15%), five of which were children. On the contrary, TERT promoter mutations were encountered in 7/28 adult patients (25%) and associated with shorter progression-free survival (log-rank test, p=0.015).
Pediatric CPTs lack recurrent driver alterations except for TP53, whereas CPTs in adults show TERT promoter mutations or a novel CCDC47-PRKCA gene fusion, being associated with a more unfavorable clinical course.
脉络丛肿瘤(CPTs)是主要发生于儿童但也会影响成人的脑室内肿瘤。在大多数情况下,尚未确定驱动突变,尽管有报道称存在频繁的全染色体拷贝数改变和TP53突变,尤其是在脉络丛癌(CPCs)中。
对一系列47例CPTs进行DNA甲基化谱分析和RNA测序。样本包括35例脉络丛乳头状瘤(CPPs)、6例非典型脉络丛乳头状瘤(aCPPs)和6例CPCs及其3例复发肿瘤。对所有样本进行靶向TP53和TERT启动子测序。分别对25例和4例样本进行全外显子测序(WES)和连接读长全基因组测序(WGS)。
肿瘤包括分子亚组“儿童A”(N = 11)、“儿童B”(N = 12)和“成人”(N = 27)。拷贝数改变主要表现为全染色体改变,并具有亚组特异性富集(“儿童B”中染色体1、2和21q的增益以及“成人”中染色体5和9的增益和染色体21q的缺失)。RNA测序在一名具有侵袭性临床病程的成人脉络丛乳头状瘤患者中产生了一种新的CCDC47-PRKCA融合转录本;连接读长WGS证实了潜在的染色体17倒位。WES和靶向测序显示47例CPTs中有7例(15%)存在TP53突变,其中5例为儿童。相反,7/28例成人患者(25%)出现TERT启动子突变,且与无进展生存期较短相关(对数秩检验,p = 0.015)。
除TP53外,儿童CPTs缺乏复发性驱动改变,而成人CPTs表现出TERT启动子突变或一种新的CCDC47-PRKCA基因融合,与更不利的临床病程相关。